Royalty Pharma Acquires a Portion of Memorial Sloan-Kettering Cancer Center’s US Royalty Interest in Neupogen/Neulasta

New York, NY, January 22, 2004 – Royalty Pharma acquired a portion of Memorial Sloan-Kettering Cancer Center’s (MSKCC) US royalty interest in Neupogen/Neulasta, the entities announced today. Under the agreement, MSKCC received $263 million in cash up-front plus certain additional payments should Neupogen/Neulasta yearly sales exceed certain agreed sales hurdles. In addition, as part of the agreement, MSKCC has made a $7 million investment in Royalty Pharma.

Source: Original Article